Company Overview

Probiomics Ltd (ASX: PCC) (formerly VRI BioMedical) was incorporated in 1997 and listed on the Australian Stock Exchange in December 2000, to fund the research and development of a portfolio of projects in mucosal immunology.

In late 2003 the Company resolved to focus primarily on the commercialisation and further development of its proven probiotic technology, with its lead probiotic, PCC®, a novel and patent protected* strain of Lactobacillus fermentum. *

 Australia Patent Nos. 2003258366 & 2003245473

Bringing science to wellness

The company's mission statement "bringing science to wellness™" signals the focus of the company on commercialising products for health maintenance and disease prevention supported by robust clinical and scientific data.

With the commencement of a molecular discovery program, the Company (VRI) coined the term Probiomics to describe the study of the molecules on probiotic bacteria which mediate the biological response in the host. Following successful completion of Stage 1 of this program, the Board decided to change the name of the Company to "Probiomics Ltd" to reflect the primary focus on probiotics and associated molecules. This change was approved by shareholders in April 2005.

The Company’s scientific and clinical research has demonstrated that PCC® has a number of unique features which could provide a competitive advantage in the market. With PCC® being supported by patent applications, Probiomics Ltd has conducting extensive (randomised, double blind, placebo-controlled) clinical trials to demonstrate the efficacy in a range of intestinal, immune and skin disorders. The data generated from the clinical trials program supports the commercialisation of the Company's probiotic products for the dietary supplements and functional food markets, on which some degree of health claims (supported by appropriate evidence) can be made. There are few companies globally that are able to do this today, thus creating a unique position for Probiomics Ltd in the probiotic market.

In November 2002 the Company concluded its first successful commercialisation agreement, with US-based Pharmanex, a subsidiary of the multi-level marketing company NuSkin Enterprises. ProBioPCC™, a probiotic-based dietary supplement which contains the Company's proprietary strain of Lactobacillus fermentum, is sold by Pharmanex through its network of distributors in North America and many Asian countries.

The experience gained from bringing this first probiotic to market has been used to bring further probiotic products to the Australian market: Progastrim®, sold exclusively to naturopaths, and proTract®, a family of products for intestinal health, diarrhoea and irritable bowel syndrome and for atopic dermatitis, which are sold exclusively through Australian pharmacies. Progastrim® and the proTract® products are listed on the Australian Register of Therapeutic Goods. Development of novel functional foods containing PCC®, and distribution of PCC®-based OTC products in other countries is underway.

The Company's Priorities

• Clinical trials - proving the clinical efficacy of PCC® via a comprehensive clinical trials program in intestinal, immune and skin disorders  through collaborations with major global companies such as Nestle.

• Product Marketing and Commercialisation - focusing on generating revenue through bringing highly effective products to a range of markets (OTC, dietary supplements, functional foods) based on the collaboration with global distributors and suppliers.

• Pharmaceutical Development - developing novel therapeutics based on PCC® and associated clinically effective molecules.

As Probiomics' primary commercialisation focus is on our current probiotic products, we have divested our original (VRI) diagnostic and vaccine IP to other entities to develop with the company recieving royalties upon commercialisation.